Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA
Trial details
- Registry ID
- NCT04360265
- Drugs studied
- Adjuvant Immunomodulatory (IM) Therapy, No Investigational Product
TrialRedline tracks 16 clinical trials sponsored by Ultragenyx Pharmaceutical Inc: 8 Phase 3, 2 Phase 2 / 3, 4 Phase 2, 2 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHNCT02716246 | Adjuvant IM Therapy, Optimized Prophylactic IM Therapy, Prophylactic Immunomodulatory (IM) Therapy, UX111 | Recruiting | 2029-03Estimated |
| Setrusumab vs Placebo for Osteogenesis ImperfectaNCT05125809 | Setrusumab | Active not recruiting | 2025-10-20Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin StudiesNCT02214160 | UX007 | Completed | 2020-12-03Actual |
| A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804NCT03118570 | Calcium, Vitamin D, setrusumab, zoledronic acid (optional) | Completed | 2019-10-01Actual |
| A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)NCT07157254 | GTX-102, No intervention | Terminated | 2026-10-30Actual |
| Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis ImperfectaNCT05312697 | Setrusumab | Terminated | 2022-07-07Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| First-in-human Study of UX016 in GNEMNCT07511556 | UX016 | Recruiting | 2028-12Estimated |
| A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson DiseaseNCT04884815 | Standard of Care (SOC) | Active not recruiting | 2029-03Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-09-17Day | UX111Ultragenyx Pharmaceutical Inc · RARE | FDA CBER biologic approvalFDA approval decision | Indicated for the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo Syndrome type A) in pediatric patients with preserved neurodevelopmental function. | Open original sourceRead source excerpt{"product": "Fayuvi rebisufligene etisparvovec-hopf", "indication": "Indicated for the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo Syndrome type A) in pediatric patients with preserved neurodevelopmental function.", "application": "125845/0", "manufacturer": "Ultragenyx Pharmaceutical Inc.", "date": "2026-09-17"} First seen: 03 Nov 2026 · Evidence last checked: 03 Nov 2026 |
Names as written in the registry records.
NCT07157254 · Ultragenyx Pharmaceutical Inc
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 55 participants (actual).
Before: Estimated. After: Actual.
Before: Jan 2030. After: 30 Oct 2026.
Before: Active not recruiting. After: Terminated.
NCT06617429 · Ultragenyx Pharmaceutical Inc
Before: Active not recruiting. After: Terminated.
NCT06415344 · Ultragenyx Pharmaceutical Inc
Before: Estimated. After: Actual.
Before: 255 participants (planned). After: 66 participants (actual).
Before: Estimated. After: Actual.
Before: Feb 2029. After: 30 Oct 2026.
Before: Active not recruiting. After: Terminated.
NCT05139316 · Ultragenyx Pharmaceutical Inc
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent Change from Baseline to Week 48 in Daily Cornstarch Intake Time frame: Baseline, Week 48. After: Measure: Main Study: Percent Change From Baseline to Week 48 in Daily Cornstarch Intake (Grams) Description: The least square (LS) mean and standard error (SE) are based on mixed-model for repeated measures (MMRM) analysis. Time frame: Baseline, Weeks 24, 30, 36, 42 and 48 Measure: Japan Cohort: Percent Change From Baseline to Week 48 in Daily Cornstarch Intake (Grams) Time frame: Baseline, Weeks 24, 30, 36, 42 and 48.
Before: 49 participants (actual). After: 52 participants (actual).
NCT06415344 · Ultragenyx Pharmaceutical Inc
Before: Enrolling by invitation. After: Active not recruiting.
NCT07157254 · Ultragenyx Pharmaceutical Inc
Before: Recruiting. After: Active not recruiting.
NCT06617429 · Ultragenyx Pharmaceutical Inc
Before: Estimated. After: Actual.
Before: Jul 2026. After: 10 Jul 2026.
NCT06415344 · Ultragenyx Pharmaceutical Inc
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Frequency, Severity, and Relationship to Investigational Drug of Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs). After: Measure: Incidence of Treatment Emergent Adverse Events (TEAEs).
NCT02716246 · Ultragenyx Pharmaceutical Inc
Before: Jul 2027. After: Mar 2029.
NCT05345171 · Ultragenyx Pharmaceutical Inc
Before: Estimated. After: Actual.
Before: 32 participants (planned). After: 37 participants (actual).
NCT05139316 · Ultragenyx Pharmaceutical Inc
Before: Active not recruiting. After: Completed.
NCT05345171 · Ultragenyx Pharmaceutical Inc
Before: Actual. After: Estimated.
Before: 19 Feb 2025. After: Sep 2027.
NCT05768854 · Ultragenyx Pharmaceutical Inc
Before: Estimated. After: Actual.
Before: Mar 2026. After: 23 Oct 2025.
NCT05125809 · Ultragenyx Pharmaceutical Inc
Before: Estimated. After: Actual.
Before: Mar 2026. After: 20 Oct 2025.